keyword
MENU ▼
Read by QxMD icon Read
search

Degludec

keyword
https://www.readbyqxmd.com/read/29777522/impact-of-insulin-degludec-in-hospitalized-patients-with-and-without-type-2-diabetes-requiring-parenteral-enteral-nutrition-an-observational-study
#1
Giuseppe Fatati, Agnese Di Donato, Ilenia Grandone, Pina Menicocci, Eva Mirri, Giuseppe Prosperini, Marco Scardapane, Maria Chiara Rossi, Mariangela Palazzi
INTRODUCTION: Hyperglycemia in inpatients is a major problem, especially when nutritional support is required. This study aims to assess the impact of treatment with insulin degludec (IDeg) on mean blood glucose (BG) and glycemic variability in noncritical hospitalized patients with and without type 2 diabetes (T2DM) receiving enteral and/or parenteral nutrition (EN, PN). METHODS: Mean BG and glycemic variability from admission up to 7 days of hospitalization were evaluated in consecutive cases with and without T2DM...
May 17, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/29770552/variability-of-insulin-degludec-and-glargine-u300-a-matter-of-methodology-or-just-marketing
#2
Tim Heise, Sascha Heckermann, J Hans DeVries
The variability in the time-action profiles of insulin preparations, in particular basal insulins, has been a matter of debate ever since the publication of a glucose clamp study comparing the day-to-day variability of three different basal insulins (glargine U100, detemir and NPH) in 2004 [1]. While critics did not contest the findings of a lower variability of some basal insulins in this and a later [2] glucose clamp study, they did question the relevance of a lower pharmacokinetic (PK) and pharmacodynamic (PD) variability for clinical endpoints [3, 4]...
May 17, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29730391/pharmacotherapy-for-hyperglycemia-in-pregnancy-the-new-insulins
#3
REVIEW
Yoel Toledano, Eran Hadar, Moshe Hod
Hyperglycemia in pregnancy may lead to adverse maternal, fetal and neonatal outcomes. Tight glycemic control is prudent in order to reduce pregnancy complications. For many years, the gold standard pharmacological therapy during pregnancy was human insulin. Recently, insulin analogues were also introduced to clinical use in pregnancy. This brief review aims to summarize the information on the efficacy and safety of insulin analogue therapy during gestation. The strengths and pitfalls of insulin analogue administration during gestation, compared with human insulin, are presented...
May 3, 2018: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/29725901/optimization-of-a-coupling-process-for-insulin-degludec-according-to-a-quality-by-design-qbd-paradigm
#4
Lei Nie, Mingming Hu, Xu Yan, Tingting Guo, Haibin Wang, Sheng Zhang, Haibin Qu
This case study described a successful application of the quality by design (QbD) principles to a coupling process development of insulin degludec. Failure mode effects analysis (FMEA) risk analysis was first used to recognize critical process parameters (CPPs). Five CPPs, including coupling temperature (Temp), pH of desB30 solution (pH), reaction time (Time), desB30 concentration (Conc), and molar equivalent of ester per mole of desB30 insulin (MolE), were then investigated using a fractional factorial design...
May 3, 2018: AAPS PharmSciTech
https://www.readbyqxmd.com/read/29721018/efficacy-and-safety-of-insulin-degludec-versus-insulin-glargine-a-systematic-review-and-meta-analysis-of-fifteen-clinical-trials
#5
REVIEW
Wei Liu, Xiaojie Yang, Jing Huang
Aims: Insulin degludec (IDeg) and insulin glargine (IGlar) are both proved to be effective in diabetes. This study aimed to assess the effects and safety of IDeg versus IGlar. Methods: A systematic literature search was conducted using the PubMed, EMBASE, and Cochrane Library electronic databases to identify all randomized controlled trials (RCTs). Results: Fifteen RCTs were identified. The combined data showed that the decrease in the glycosylated hemoglobin (HbA1c) level was slightly different, and the proportion of patients who achieved HbA1c < 7% was similar between the IDeg and IGlar groups...
2018: International Journal of Endocrinology
https://www.readbyqxmd.com/read/29720273/when-insulin-degludec-enhances-quality-of-life-in-patients-with-type-2-diabetes-a-qualitative-investigation
#6
James Weatherall, William H Polonsky, Sally Lanar, Naomi Knoble, Jonas Håkan-Bloch, Elisabeth Constam, Athena Philis-Tsimikas, Alexia Marrel
BACKGROUND: Anecdotal reports suggest that insulin degludec (IDeg) may offer unique health-related quality of life (HRQoL) benefits. As the nature of these benefits remain unclear, this study utilized qualitative research methods to investigate and elucidate the experience of "feeling better" after initiating IDeg. METHODS: Twenty adults with type 2 diabetes (T2D) who reported "feeling better" on IDeg for > 3 months participated in 90-min interviews...
May 3, 2018: Health and Quality of Life Outcomes
https://www.readbyqxmd.com/read/29719376/theoretical-overview-of-clinical-and-pharmacological-aspects-of-the-use-of-etelcalcetide-in-diabetic-patients-undergoing-hemodialysis
#7
REVIEW
Jianzhen Ye, Guangrui Deng, Feng Gao
Etelcalcetide is the first intravenous calcimimetic agent authorized for the treatment of secondary hyperparathyroidism (sHPT) in patients undergoing hemodialysis in Europe, the US, and Japan. The relationship between sHPT and diabetes resides on complex, bidirectional effects and largely unknown homeostatic mechanisms. Although 30% or more patients with end-stage renal disease are diabetics and about the same percentage of those patients suffer from sHPT associated with hemodialysis, no data on the specificities of the use of etelcalcetide in such patients are available yet...
2018: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/29718785/finally-after-56-years-of-type-1-diabetes-a-regimen-that-works
#8
David S H Bell
Prior to the availability of degludec and regular human insulin inhalation powder in the type 1 diabetic patient glycemic control with subcutaneous insulin injections was difficult to obtain due to nocturnal, pre-prandial and often severe hypoglycemia as well as post-prandial hyperglycemia and hypoglycemia due to 'stacking' of insulin. A 62-year-old female with type 1 diabetes for 56 years who could not be controlled with continuous subcutaneous insulin aspart infusion obtained glycemic control without significant hypoglycemia or increased post-prandial glycemic excursions utilizing degludec insulin for basal needs and technosphere before meals and between meals if needed...
May 14, 2018: Postgraduate Medicine
https://www.readbyqxmd.com/read/29713962/devote-5-evaluating-the-short-term-cost-utility-of-insulin-degludec-versus-insulin-glargine-u100-in-basal-bolus-regimens-for-type-2-diabetes-in-the-uk
#9
Richard F Pollock, William J Valentine, Steven P Marso, Jens Gundgaard, Nino Hallén, Lars L Hansen, Deniz Tutkunkardas, John B Buse
INTRODUCTION: The aim of this study was to evaluate the short-term cost-utility of insulin degludec (degludec) versus insulin glargine 100 units/mL (glargine U100) for the treatment of type 2 diabetes in the basal-bolus subgroup of the head-to-head cardiovascular (CV) outcome trial, DEVOTE. METHODS: A cost-utility analysis was conducted over a 2-year time horizon using a decision analytic model to compare costs in patients receiving once daily degludec or glargine U100, both as part of a basal-bolus regimen, in addition to standard care...
April 30, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29700772/cost-effectiveness-of-insulin-degludec-versus-insulin-glargine-u100-in-patients-with-type-1-and-type-2-diabetes-mellitus-in-serbia
#10
Nebojša Lalić, Monika Russel-Szymczyk, Marina Culic, Christian Klyver Tikkanen, Barrie Chubb
INTRODUCTION: This study investigates the cost-effectiveness of insulin degludec versus insulin glargine U100 in patients with type 1 and type 2 diabetes mellitus in Serbia. METHODS: A cost-utility analysis, implementing a simple short-term model, was used to compare treatment costs and outcomes with degludec versus glargine U100 in patients with type 1 (T1DM) and type 2 diabetes (T2DM). Cost-effectiveness was analysed in a 1-year setting, based on data from clinical trials...
April 26, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29686457/initiating-titratable-fixed-ratio-combinations-of-basal-insulin-analogs-and-glucagon-like-peptide-1-receptor-agonists-what-you-need-to-know
#11
Neil Skolnik, Debbie Hinnen, Yan Kiriakov, Melissa L Magwire, John R White
IN BRIEF Titratable fixed-ratio combinations (FRCs) of a basal insulin and a glucagon-like peptide-1 (GLP-1) receptor agonist are new therapeutic options for people with type 2 diabetes. Two FRCs-insulin degludec/liraglutide and insulin glargine/lixisenatide-have been approved for use in the United States. The two components in these FRCs target different aspects of diabetes pathophysiology, working in a complementary manner to decrease blood glucose while mitigating the side effects associated with each component (hypoglycemia and weight gain with insulin and gastrointestinal side effects with GLP-1 receptor agonists)...
April 2018: Clinical Diabetes: a Publication of the American Diabetes Association
https://www.readbyqxmd.com/read/29686454/safety-and-efficacy-of-insulin-degludec-liraglutide-ideglira-and-insulin-glargine-u100-lixisenatide-iglarlixi-two-novel-co-formulations-of-a-basal-insulin-and-a-glucagon-like-peptide-1-receptor-agonist-in-patients-with-diabetes-not-adequately-controlled-on
#12
Carol H Wysham, Carlos Campos, Davida Kruger
IN BRIEF Novel co-formulations of basal insulin analogs and glucagon-like peptide-1 (GLP-1) receptor agonists have provided new options for patients with type 2 diabetes who are not reaching recommended glycemic targets. The components of currently available co-formulations (insulin degludec/ liraglutide [IDegLira,] and insulin glargine U100/lixisenatide [iGlarLixi]) act synergistically to address multiple pathophysiologic defects while minimizing the side effects associated with either component when used alone...
April 2018: Clinical Diabetes: a Publication of the American Diabetes Association
https://www.readbyqxmd.com/read/29686453/insulin-glucagon-like-peptide-1-receptor-agonist-combination-therapy-for-the-treatment-of-type-2-diabetes-are-two-agents-better-than-one
#13
Vanita R Aroda, Joseph R Arulandu, Anthony J Cannon
IN BRIEF Given the progressive nature of type 2 diabetes, treatment intensification is usually necessary to maintain glycemic control. However, for a variety of reasons, treatment is often not intensified in a timely manner. The combined use of basal insulin and a glucagon-like peptide-1 receptor agonist is recognized to provide a complementary approach to the treatment of type 2 diabetes. This review evaluates the efficacy and safety of two co-formulation products, insulin degludec/liraglutide and insulin glargine/lixisenatide, for the treatment of type 2 diabetes inadequately controlled on either component agent alone...
April 2018: Clinical Diabetes: a Publication of the American Diabetes Association
https://www.readbyqxmd.com/read/29686452/how-does-diabetes-affect-daily-life-a-beyond-a1c-perspective-on-unmet-needs
#14
Divya Gopisetty, Brian Levine, Nancy Liu, Phin Younge, Adam Brown, Kelly L Close, Richard Wood
IN BRIEF Given the progressive nature of type 2 diabetes, treatment intensification is usually necessary to maintain glycemic control. However, for a variety of reasons, treatment is often not intensified in a timely manner. The combined use of basal insulin and a glucagon-like peptide-1 receptor agonist is recognized to provide a complementary approach to the treatment of type 2 diabetes. This review evaluates the efficacy and safety of two co-formulation products, insulin degludec/liraglutide and insulin glargine/lixisenatide, for the treatment of type 2 diabetes inadequately controlled on either component agent alone...
April 2018: Clinical Diabetes: a Publication of the American Diabetes Association
https://www.readbyqxmd.com/read/29620817/evaluating-the-managed-care-implications-of-longer-acting-basal-insulin-analog-therapies
#15
Tripp Logan, Bianca Daisy
Diabetes, particularly type 2 diabetes (T2D), has become an epidemic in the United States, with a significant portion of patients unable to meet recommended glycemic targets. All individuals with type 1 diabetes (T1D) and a significant majority of those with T2D will ultimately require insulin therapy. However, there are several barriers to its use. The introduction of the new, ultra-long-acting basal insulins degludec and glargine U-300, and the single-injection combinations of insulin degludec/liraglutide and insulin glargine U-100/lixisenatide, offer options that may overcome several of those barriers, including the high risk of hypoglycemia, glycemic variability, and relatively short duration of action...
March 2018: American Journal of Managed Care
https://www.readbyqxmd.com/read/29619381/efficacy-and-safety-of-insulin-glargine-300-u-ml-versus-100-u-ml-in-diabetes-mellitus-a-comprehensive-review-of-the-literature
#16
REVIEW
Hernando Vargas-Uricoechea
To achieve good metabolic control in diabetes and maintain it in the long term, a combination of changes in lifestyle and pharmacological treatment is necessary. The need for insulin depends upon the balance between insulin secretion and insulin resistance. Insulin is considered the most effective glucose-lowering therapy available and is required by people with type 1 diabetes mellitus to control their blood glucose levels; yet, many people with type 2 diabetes mellitus will also eventually require insulin therapy, due to the progressive nature of the disease...
2018: Journal of Diabetes Research
https://www.readbyqxmd.com/read/29619208/conversion-from-insulin-glargine-u-100-to-insulin-glargine-u-300-or-insulin-degludec-and-the-impact-on-dosage-requirements
#17
Scott M Pearson, Jennifer M Trujillo
Background: We wanted to determine whether basal insulin requirements change when patients transition from insulin glargine U-100 (Gla-100) to insulin glargine U-300 (Gla-300) or insulin degludec. Methods: This study involved subjects seen in the University of Colorado Health Endocrine Clinic who were transitioned from Gla-100 to either Gla-300 ( n = 95) or insulin degludec ( n = 39). The primary outcome was the difference between baseline Gla-100 dose and dose of Gla-300 or insulin degludec prescribed after first follow-up visit within 1-12 months...
April 2018: Therapeutic Advances in Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29610753/insulin-degludec-u100-is-associated-with-lower-risk-for-severe-and-symptomatic-hypoglycemia-as-compared-with-insulin-glargine-u100-in-subjects-with-type-1-diabetes
#18
EDITORIAL
Anastasios Tentolouris, Ioanna Eleftheriadou, Nikolaos Tentolouris
No abstract text is available yet for this article.
February 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29603806/glucose-concentrations-after-insulin-induced-hypoglycemia-and-glycemic-variability-in-healthy-and-diabetic-cats
#19
Eric Zini, Elena Salesov, Perrine Dupont, Laura Moretto, Barbara Contiero, Thomas A Lutz, Claudia E Reusch
BACKGROUND: Little information is available about posthypoglycemic hyperglycemia (PHH) in diabetic cats, and a causal link between hypoglycemia and subsequent hyperglycemia is not clear. Fluctuations in blood glucose concentrations might only represent high glycemic variability. HYPOTHESIS: Insulin induces PHH in healthy cats, and PHH is associated with poorly regulated diabetes and increased glycemic variability in diabetic cats. ANIMALS: Six healthy cats, 133 diabetic cats...
March 30, 2018: Journal of Veterinary Internal Medicine
https://www.readbyqxmd.com/read/29596514/characterisation-of-insulin-analogues-therapeutically-available-to-patients
#20
Gary G Adams, Andrew Meal, Paul S Morgan, Qushmua E Alzahrani, Hanne Zobel, Ryan Lithgo, M Samil Kok, David T M Besong, Shahwar I Jiwani, Simon Ballance, Stephen E Harding, Naomi Chayen, Richard B Gillis
The structure and function of clinical dosage insulin and its analogues were assessed. This included 'native insulins' (human recombinant, bovine, porcine), 'fast-acting analogues' (aspart, glulisine, lispro) and 'slow-acting analogues' (glargine, detemir, degludec). Analytical ultracentrifugation, both sedimentation velocity and equilibrium experiments, were employed to yield distributions of both molar mass and sedimentation coefficient of all nine insulins. Size exclusion chromatography, coupled to multi-angle light scattering, was also used to explore the function of these analogues...
2018: PloS One
keyword
keyword
10126
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"